Earnings Call Insights: Co-Diagnostics (CODX) Q1 2026 Management View "This continues to be an active and important period for our business as we execute on the opportunities ahead and remain focused on positioning the company for its next phase of growth," said (Chairman, CEO & President Dwight Egan), highlighting priorities including "advancing our clinical and commercialization pipeline," India...
Earnings Call Insights: Co-Diagnostics (CODX) Q1 2026 Management View "This continues to be an active and important period for our business as we execute on the opportunities ahead and remain focused on positioning the company for its next phase of growth," said (Chairman, CEO & President Dwight Egan), highlighting priorities including "advancing our clinical and commercialization pipeline," India via CoSara, Saudi Arabia via CoMira, and "enhancing our platform through connectivity, automation and AI-driven capabilities." On the U.S. upper respiratory multiplex program, (Chairman, CEO & President Dwight Egan) said, "We have now completed enrollment in the clinical study, with more than 1,400 patients enrolled," and added, "Based on current epidemiological conditions, COVID prevalence was lower than expected," leading to "an initial submission focused on Flu A, Flu B and RSV" while retaining flexibility to add COVID later. On India, (Chairman, CEO & President Dwight Egan) said, "CoSara has a nationwide commercial presence, has served hundreds of laboratory customers and has 15 clinical laboratory PCR tests cleared by the CDSCO," and added, "CoSara has also now received a CDSCO license to manufacture the PCR Pro instrument." He also stated, "We have expanded CoSara's commercial and distribution territory across South Asia, increasing our total addressable market to approximately $13 billion." On potential strategic alternatives for CoSara, (Chairman, CEO & President Egan) said, "We continue to evaluate the strategic alternatives, including a potential SPAC transaction," while cautioning, "No transaction has been agreed to, and there can be no assurance that any transaction will result from these discussions." CFO (CFO & Company Secretary Brian Brown) summarized the quarter’s financial profile and funding needs: "For the first quarter of 2026, total revenue was $146,000," "net loss for the quarter was $9.1 million or $4.06 per fully diluted share," "we ended the quarte...